20 years of Modifying Stroke Risk in Sickle Cell Disease (SCD) Patients: a Single Center Experience of Bone Marrow Transplant (BMT) in SCD (P6.256)

Conclusions:While BMT is curative for SCD, the impact on cerebral vasculopathy and ongoing stroke risk is unknown. Data from this sample suggests that BMT is associated with stabilization but not resolution of vasculopathy and dramatic reduction of stroke after the first year.Study Supported by:N/ADisclosure: Dr. Carpenter has nothing to disclose. Dr. Farias Moeller has nothing to disclose. Dr. Abraham has nothing to disclose. Dr. Khademian has nothing to disclose.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Carpenter, J., Moeller, R. F., Abraham, A., Khademian, Z. Tags: Non-Atherosclerotic Angiopathies and Cerebral Venous Thrombosis Source Type: research